Navigation Links
What Patients Need to Know about Acetaminophen

BOSTON, Nov. 12, 2012 /PRNewswire/ -- The misuse of acetaminophen is the leading cause of acute liver failure in the West. Informed patients and clearly labeled prescription bottles are necessary to avoid accidental overdoses. Patients with new prescriptions often are unaware of the presence of acetaminophen in their new drug nor do they recall their prescribers' advice concerning acetaminophen, according to researchers at Northwestern University who examined the behavior of 249 patients who were either discharged from a hospital emergency room or recently visited an outpatient pharmacy.

Only 25.7 percent of patients could recall counseling concerning acetaminophen from their prescribers. According to Dr. Marina Serper of The Health Literacy and Learning Program at Northwestern University, "When prescribing an acetaminophen-containing medication, healthcare providers should clearly state the active ingredients in the medication. Providers should explain what constitutes the daily maximum dose of this medication and how it may or may not be combined with other common over the counter acetaminophen preparations."

Researchers asked patients to keep a diary of the medications they had taken in the first seven days after starting their new prescription. All patients were interviewed after seven days to determine the presence of warning labels on bottles, the total amount and sources of acetaminophen taken, patients' knowledge of active ingredients in prescriptions, and patient recall of any communication concerning acetaminophen with the prescriber.

The study also addressed what Dr. Serper refers to as, "the lack of uniformity of prescription labeling." Only 26.9 percent of patients studied correctly identified acetaminophen as an ingredient in their prescription medication. Researchers reported 10.8 percent of those patients studied "double-dipped," meaning that they took their new prescription along with another product containing acetaminophen on the same day – most often an over the counter pain medication.

Four of the 249 patients (1.6 percent) exceeded the recommended daily dose of 4 grams. "In our anecdotal experience, patients do not always understand the meaning of 4000 mg or 4 g and it is more helpful to say something like, 'you should not take more than 8 pills of this medication per day," said Dr. Serper.

Compounding the confusion was that acetaminophen was identified by one of two abbreviations (APAP or ACET) on the prescription label 87.3 percent of the time, and only 59 percent of those prescription bottles had an acetaminophen warning. Dr. Serper addressed this point, "It is equally and perhaps more important to have clear and universal labeling of acetaminophen on prescription bottles, something which does not routinely occur, as shown by our study."

The general confusion faced by patients who are unaware of the active ingredients in their prescription medication because of insufficient or inconsistent labeling of ingredients and warnings, as well as insufficient counseling by prescribers, can put patients in danger of exceeding the daily recommended dose of acetaminophen which can lead to acute liver failure. Researchers concluded that the elimination of abbreviations on prescription labels and more consistent verbal counseling from healthcare providers was needed to minimize this danger.

Abstract title:

Active Ingredient Confusion for Acetaminophen-Containing Medications: A Cause of Double Dipping

AASLD is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent and cure liver diseases. This year's Liver Meeting®, held in Boston, Massachusetts November 9 – 13, will bring together more than 9,000 researchers from 55 countries.

A pressroom will be available from November 10 at the annual meeting. For copies of abstracts and press releases, or to arrange researcher interviews, contact Gregory Bologna at 703-299-9766. Press releases and all abstracts are available online at Media Contact: Gregory Bologna703/ Press Room: November 10 – 13, 2012Hynes Convention Center, Boston, MATelephone: 617-954-2624Researcher: Marina Serper, MDEmail: Phone: 312-503-3193  This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit

SOURCE American Association for the Study of Liver Diseases (AASLD)
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
2. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
3. Phreesia identifies over 26% of patients who require additional autism evaluation
4. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
5. New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinsons disease
6. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
7. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
8. Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients
9. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Italian therapeutic drug monitoring market, including emerging tests, ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Marker Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/25/2015)...  The total global healthcare industry is expected to grow ... Latin America has the highest projected growth at ... Japan ), is second with growth projected at 11.5%. ... healthcare expenditure. In 2013-2014, total government funded healthcare was nearly ... to 41.2% in 2013-2014. In real terms, out of pocket ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film Studios brings ... with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired ... font, giving users limitless opportunities to stylize and create designs quickly and easily, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast ... found on mammography, according to a study published online in the journal Radiology. ... on mammography may necessitate a change in treatment. , Breast MRI is the ...
(Date:11/25/2015)... Cokato, MN (PRWEB) , ... November 25, 2015 , ... ... Thanksgiving through Christmas Eve on several models of traditional and far-infrared saunas. ... . Nordic Spruce is the most traditional Finnish sauna wood, and Finnleo uses only ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Dr. John Pierce, ... learn more about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA ... for thicker and fuller hair, without the need for surgery, prescription pills, or topical ...
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to MAP ... the two groups began in 2014 with Vitalalert pledging a portion of every purchase ... in 1954 and is an international Christian-based health organization whose mission is to “advance ...
Breaking Medicine News(10 mins):